Biogen Inc (BIIB)
264.11
-2.49 -0.93%
NASDAQ
Mar 4, 16:11
USD
View All Key Stats
Key Stats
Income Statement | |
Revenue (TTM) | 13.44B |
Revenue (Quarterly YoY Growth) | Upgrade |
EPS Diluted (TTM) | 24.45 |
EPS Diluted (Quarterly YoY Growth) | Upgrade |
Net Income (TTM) | 4.001B |
Profitability | |
Gross Profit Margin (Quarterly) | 82.80% |
Profit Margin (Quarterly) | 12.55% |
Dividend | |
Dividend Yield (Forward) | Upgrade |
Dividend Yield | 0% |
Price and Valuation | |
Market Cap | 40.23B |
52 Week High (Daily) | Upgrade |
52 Week Low (Daily) | Upgrade |
PS Ratio | 3.169 |
PE Ratio | 10.80 |
Price to Book Value | 3.760 |
Other | |
Beta (5Y) | Upgrade |
Debt to Equity Ratio | 0.694 |
Free Cash Flow (Quarterly) | -468.10M |
Return on Equity | Upgrade |
View All BIIB News
News
-
WireHeadlineTime (ET)
-
SA Breaking News03/04 08:18
-
MT Newswires03/04 08:09
-
Yahoo03/04 08:06
-
Globe Newswire03/04 07:47
-
Yahoo03/03 08:15
-
Yahoo03/01 17:11
-
Yahoo02/26 13:16
-
Yahoo02/24 16:28
-
Yahoo02/24 16:11
-
Globe Newswire02/24 07:30
-
Yahoo02/24 06:53
-
Yahoo02/23 06:30
-
Yahoo02/20 06:12
-
MT Newswires02/17 10:19
-
Yahoo02/16 16:16
-
SA Breaking News02/16 10:03
-
SA Breaking News02/13 16:00
-
Yahoo02/12 10:00
-
Yahoo02/12 09:23
-
Yahoo02/12 06:25
View All Events
Events
Date | Type | Description |
---|---|---|
04/22/2021 | Earnings | Biogen Inc First Quarter Earnings Results for 2021 |
04/22/2021 | Misc | Biogen Inc First Quarter Earnings Conference Call for 2021 |
02/03/2021 | Earnings | Biogen Inc Fourth Quarter Earnings Result for 2020 |
02/03/2021 08:00 EST | Misc | Biogen Inc Fourth Quarter Earnings Conference Call for 2020 |
02/03/2021 | Misc | Biogen Inc Annual Report for 2020 |
10/21/2020 | Earnings | Biogen Inc Third Quarter Earnings Result for 2020 |
10/21/2020 08:00 EDT | Misc | Biogen Inc Third Quarter Earnings Conference Call for 2020 |
07/22/2020 08:00 EDT | Misc | Biogen Inc Second Quarter Earnings Conference Call for 2020 |
07/22/2020 | Earnings | Biogen Inc Second Quarter Earnings Result for 2020 |
06/03/2020 09:00 EDT | Misc | Biogen Inc Annual General Meeting for 2019 |
Fundamentals
Income Statement View Statement
Ratings & Reports
- Y-Rating Upgrade
- Value Score Upgrade
- Fundamental Score Upgrade
- Valuation (Hist. Mult.) Upgrade
- Y-Rating Report Download
- One Page Report Download
Advertisement
Edit
Profile
- URL: http://www.biogen.com
- Investor Relations URL: https://www.biogen.com/en_us/investors.html
- HQ State/Province: Massachusetts
- Sector: Healthcare
- Industry: Drug Manufacturers - General
- Equity Style: Large Cap/Value
- Next Earnings Release: Apr. 22, 2021
- Last Earnings Release: Feb. 03, 2021
- Next Ex-Dividend Date: N/A
- Last Ex-Dividend Date: N/A
- Description: Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis.
Analyst Coverage
Consensus Recommendations | |
Buy Recommendations | Upgrade |
Outperform Recommendations | Upgrade |
Hold Recommendations | Upgrade |
Underperform Recommendations | Upgrade |
Sell Recommendations | Upgrade |
Consensus Recommendation | Upgrade |
Consensus Rating | Upgrade |
Target Price | |
Price | 264.11 |
Price Target | Upgrade |
Price Target Upside (Daily) | Upgrade |
Top Fund Holders
Symbol | Name | Weighting |
---|---|---|
LMPFX | ClearBridge Aggressive Growth FI | 5.41% |
PKW | Invesco BuyBack Achievers ETF | 5.23% |
FBT | First Trust NYSE Arca Biotech ETF | 3.50% |
IBB | iShares Nasdaq Biotechnology ETF | 3.45% |
FBIOX | Fidelity® Select Biotechnology | 3.33% |
VPMCX | Vanguard PRIMECAP Inv | 3.18% |
VHCOX | Vanguard Capital Opportunity Inv | 2.59% |
VPCCX | Vanguard PRIMECAP Core Inv | 2.43% |
MOAT | VanEck Vectors Morningstar Wide Moat ETF | 2.36% |
FXH | First Trust Health Care AlphaDEX® ETF | 2.20% |
VGHCX | Vanguard Health Care Inv | 2.11% |
XBI | SPDR® S&P Biotech ETF | 1.00% |
Other Resources
- 13F Filings Whale Wisdom
- Call Transcripts Seeking Alpha
- Insider Trading Morningstar
- Institutional Ownership Nasdaq
- SEC Filings SEC
- BIIB Tweets Stocktwits
Advertisement